|drug2198||Nitazoxanide and atazanavir/ritonavir Wiki||1.00|
|drug3221||Standard of Care Wiki||0.16|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
COVID-19's mechanism to enter the cell is initiated by its interaction with its cellular receptor, the angiotensin-converting enzyme. As a result of this union, a clathrin-mediated endocytosis process begins. This route is one of the therapeutic targets for which available drugs are being investigated in order to treat COVID-19 infection. This is one of the mechanisms blocked by drugs like ruxolitinib and chloroquine. Various drugs approved for clinical use that block the clathrin-mediated endocytosis pathway have been explored. It has been found that the best in vitro and in vivo results were obtained with statins, which also allowed generating a greater potent adaptive immune response. Therefore, statins and specifically simvastatin make it possible to block the entry process used by COVID-19, block inflammation by various mechanisms and increase the adaptive immune response. All of these processes are desirable in patients infected with COVID-19. Statins have been proposed to have beneficial effects in patients infected with MERS-COV, another coronavirus similar to COVID-19, but there have been no randomized studies supporting the use of statins in patients with COVID-19 infection. In this project we propose the combined use of one of these drugs, ruxolitinib with simvastatin, looking for a synergistic effect in the inhibition of viral entry and in the anti-inflammatory effect.
Description: Patients achieving a grade 5 or higher of the WHO 7-point ordinal scale of severity categorization for COVID at day 7 from randomization.Measure: Percentage of patients who develop severe respiratory failure. Time: 7 days
Description: Patients achieving a grade 5 or higher of the WHO 7-point ordinal scale of severity categorization for COVID at day 14 from randomization.Measure: Percentage of patients who develop severe respiratory failure. Time: 14 days
Description: Time from ICU admision to ICU discharge.Measure: Length of ICU stay. Time: 28 days
Description: Time from hospital admision to hospital discharge.Measure: Length of hospital stay Time: 28 days
Description: Percentage of patients alive at 6 monthsMeasure: Survival rate at 6 months Time: 6 months
Description: Percentage of patients alive at 12 monthsMeasure: Survival rate at 12 months Time: 12 months
Description: Percentage of patients who died from any cause 28 days after inclusion in the studyMeasure: Survival rate at 28 days Time: 28 days
Description: Percentage of patients with each AE by grade in relation with total number of treated patientsMeasure: Percentage of patients with each AE by grade Time: 28 days
Description: Percentage of patients who discontinued due to AEs in relation with total number of treated patientsMeasure: Percentage of patients who discontinued due to AEs Time: 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports